Endothelium and cardioprotective effects of hmg-co-a-reductase in combination with L-arginine in endothelial dysfunction modeling
| Autor: | A.A. Shaposhnikov, T.A. Denisyuk, G.A. Lazareva, V.Ya. Provotorov |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
endotoxin
HMG-Co-A reductase inhibi medicine Arginine Endothelium Atorvastatin HMG-Co-A reductase inhibitor simvastatin RM1-950 Pharmacology endothelial dysfunction Pharmacology (medical) Rosuvastatin cardiovascular diseases Endothelial dysfunction Hmg co a reductase business.industry nutritional and metabolic diseases atorvastatin medicine.disease medicine.anatomical_structure lipids (amino acids peptides and proteins) Therapeutics. Pharmacology pharmacology business rosuvastatin medicine.drug |
| Zdroj: | Research Results in Pharmacology, Vol 2, Iss 1, Pp 4-8 (2016) Research Results in Pharmacology 2(1): 4-8 |
| ISSN: | 2658-381X |
| Popis: | Using the combined application of L-arginine with HMG-Co-A reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of modeling of sepsis-induced disease through the introduction of strain 603 Staphylococcus aureus shows endotelio- and cardioprotective effects, manifesting itself in preventing the proliferation of endothelial dysfunction coefficient (CED), adrenoreactivity, maintenance of myocardial reserve and the normalization of biochemical markers values (Total NO, eNOS expression, C-reactive protein, IL-6, TNF). In this case, the combined therapy was so effective that the values obtained thereunder did not differ from those obtained from control animals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|